Focus on the cutting edge, dedicated to protection.
Stay tuned for the latest updates from BIOALLY.
2025-11-10
Recently, in a laboratory at China Pharmaceutical City in Taizhou, Jiangsu Province, recombinant feline omega-interferon is undergoing pre-market stability studies, with the compilation and analysis of key data now in the final stages. Researchers are holding their breath, as this small pharmaceutical product—alongside the “Miaobeihu” feline trivalent inactivated vaccine, which was just approved here two months ago—represents not only a breakthrough from zero to one in China’s pet biopharmaceutical sector, but also signals the emergence of a formidable “Chinese force” in an industry long dominated by international giants.
Learn more
2025-10-15
On September 16, 2025, the Ministry of Agriculture and Rural Affairs issued Announcement No. 949: Recombinant feline interferon-α, independently developed by Taizhou BioAlly Biotechnology Co., Ltd., has been successfully approved for registration as a Class II new veterinary drug at the national level. This marks China’s first—and the world’s second—approved recombinant feline interferon, as well as the world’s first interferon product with dual applications: both injectable and ophthalmic. This milestone breakthrough not only signifies that China’s research and development in pet genetic engineering pharmaceuticals has entered the ranks of international leaders, but also fully demonstrates BioAlly’s outstanding capacity for technological innovation. Committed to independent R&D.
Learn more
2025-10-13
MeowCare Standard Immunization Protocol
Throughout a cat’s life, vaccination serves as a robust line of defense, effectively warding off disease and safeguarding their health. Now, let’s explore the standardized procedures for Miao Beihu’s immunization program, ensuring that every feline companion thrives and grows strong.
Learn more
